title: Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.
abstract: Accelerated atherosclerosis and vascular calcifications (VC) play a central role in the pathogenesis of cardiovascular disease in chronic kidney disease (CKD) patients. Mineral metabolism disorders and increased serum calcium-phosphate product have been recently investigated as inducing factors of cardiovascular calcification. In fact, cardiovascular disease in renal failure appears greatly associated with bone metabolism alterations. Recently, the treatment of hyperphosphatemia in CKD patients changed from either calcium- or aluminium-based phosphate-binders to new free-calcium and aluminium phosphate binders, such as sevelamer hydrochloride and lanthanum carbonate. Therefore, control of serum phosphate in CKD patients becomes crucial in preventing increases in calcium-phosphate product, secondary hyperparathyroidism and ultimately VC.
authors.forename: Mario
authors.initials: M
authors.lastname: Cozzolino
authors.forename: Diego
authors.initials: D
authors.lastname: Brancaccio
mesh_terms: D050197:Atherosclerosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D002114:Calcinosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D002130:Calcium Phosphates / Q000097:blood; D002614:Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D007811:Lanthanum / Q000627:therapeutic use; D010710:Phosphates / Q000097:blood* / Q000378:metabolism; D010760:Phosphorus Metabolism Disorders / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D011073:Polyamines / Q000627:therapeutic use; D006435:Renal Dialysis; D000069603:Sevelamer; D014511:Uremia / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000209:etiology
chemical_list: D002130:Calcium Phosphates; D002614:Chelating Agents; D015507:Drugs, Investigational; D010710:Phosphates; D011073:Polyamines; C119467:lanthanum carbonate; D007811:Lanthanum; D000069603:Sevelamer